Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma

Cara B Gonzales, Jorge J. De La Chapa, Pothana Saikumar, Prajjal K. Singha, Nicholas F. Dybdal-Hargreaves, Jeffery Chavez, Aaron M. Horning, Jamie Parra, Nameer B Kirma

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Squamous cell carcinoma (SCC) comprises 90% of all head and neck cancers and has a poor survival rate due to late-stage disease that is refractive to traditional therapies. Epidermal growth factor receptor (EGFR) is over-expressed in greater than 80% of head and neck SCC (HNSCC). However, EGFR targeted therapies yielded little to no efficacy in clinical trials. This study investigated the efficacy of co-targeting EGFR and the anaplastic lymphoma kinase (ALK) whose promoter is hypomethylated in late-stage oral SCC (OSCC). We observed increased ALK activity in late-stage human OSCC tumors and invasive OSCC cell lines. We also found that while ALK inhibition alone had little effect on proliferation, co-targeting ALK and EGFR significantly reduced OSCC cell proliferation in vitro. Further analysis showed significant efficacy of combined treatment in HSC3-derived xenografts resulting in a 30% decrease in tumor volumes by 14 days (p < 0.001). Western blot analysis showed that co-targeting ALK and EGFR significantly reduced EGFR phosphorylation (Y1148) in HSC3 cells but not Cal27 cells. ALK and EGFR downstream signaling interactions are also demonstrated by Western blot analysis in which lone EGFR and ALK inhibitors attenuated AKT activity whereas co-targeting ALK and EGFR completely abolished AKT activation. No effects were observed on ERK1/2 activation. STAT3 activity was significantly induced by lone ALK inhibition in HSC3 cells and to a lower extent in Cal27 cells. Together, these data illustrate that ALK inhibitors enhance anti-tumor activity of EGFR inhibitors in susceptible tumors that display increased ALK expression, most likely through abolition of AKT activation.

Original languageEnglish (US)
Pages (from-to)12-19
Number of pages8
JournalOral Oncology
Volume59
DOIs
StatePublished - 2016

Fingerprint

Epidermal Growth Factor Receptor
Squamous Cell Carcinoma
Oral Stage
anaplastic lymphoma kinase
Western Blotting
Neoplasms
Head and Neck Neoplasms
Tumor Burden
Heterografts
Phosphorylation
Cell Proliferation
Clinical Trials
Cell Line

Keywords

  • Anaplastic lymphoma kinase
  • Epidermal growth factor receptor
  • Head and neck cancer
  • Oral squamous cell carcinoma

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Gonzales, C. B., De La Chapa, J. J., Saikumar, P., Singha, P. K., Dybdal-Hargreaves, N. F., Chavez, J., ... Kirma, N. B. (2016). Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma. Oral Oncology, 59, 12-19. https://doi.org/10.1016/j.oraloncology.2016.05.007

Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma. / Gonzales, Cara B; De La Chapa, Jorge J.; Saikumar, Pothana; Singha, Prajjal K.; Dybdal-Hargreaves, Nicholas F.; Chavez, Jeffery; Horning, Aaron M.; Parra, Jamie; Kirma, Nameer B.

In: Oral Oncology, Vol. 59, 2016, p. 12-19.

Research output: Contribution to journalArticle

Gonzales, CB, De La Chapa, JJ, Saikumar, P, Singha, PK, Dybdal-Hargreaves, NF, Chavez, J, Horning, AM, Parra, J & Kirma, NB 2016, 'Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma', Oral Oncology, vol. 59, pp. 12-19. https://doi.org/10.1016/j.oraloncology.2016.05.007
Gonzales, Cara B ; De La Chapa, Jorge J. ; Saikumar, Pothana ; Singha, Prajjal K. ; Dybdal-Hargreaves, Nicholas F. ; Chavez, Jeffery ; Horning, Aaron M. ; Parra, Jamie ; Kirma, Nameer B. / Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma. In: Oral Oncology. 2016 ; Vol. 59. pp. 12-19.
@article{cae6c052550b4b58bcfd04beade6dc4f,
title = "Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma",
abstract = "Squamous cell carcinoma (SCC) comprises 90{\%} of all head and neck cancers and has a poor survival rate due to late-stage disease that is refractive to traditional therapies. Epidermal growth factor receptor (EGFR) is over-expressed in greater than 80{\%} of head and neck SCC (HNSCC). However, EGFR targeted therapies yielded little to no efficacy in clinical trials. This study investigated the efficacy of co-targeting EGFR and the anaplastic lymphoma kinase (ALK) whose promoter is hypomethylated in late-stage oral SCC (OSCC). We observed increased ALK activity in late-stage human OSCC tumors and invasive OSCC cell lines. We also found that while ALK inhibition alone had little effect on proliferation, co-targeting ALK and EGFR significantly reduced OSCC cell proliferation in vitro. Further analysis showed significant efficacy of combined treatment in HSC3-derived xenografts resulting in a 30{\%} decrease in tumor volumes by 14 days (p < 0.001). Western blot analysis showed that co-targeting ALK and EGFR significantly reduced EGFR phosphorylation (Y1148) in HSC3 cells but not Cal27 cells. ALK and EGFR downstream signaling interactions are also demonstrated by Western blot analysis in which lone EGFR and ALK inhibitors attenuated AKT activity whereas co-targeting ALK and EGFR completely abolished AKT activation. No effects were observed on ERK1/2 activation. STAT3 activity was significantly induced by lone ALK inhibition in HSC3 cells and to a lower extent in Cal27 cells. Together, these data illustrate that ALK inhibitors enhance anti-tumor activity of EGFR inhibitors in susceptible tumors that display increased ALK expression, most likely through abolition of AKT activation.",
keywords = "Anaplastic lymphoma kinase, Epidermal growth factor receptor, Head and neck cancer, Oral squamous cell carcinoma",
author = "Gonzales, {Cara B} and {De La Chapa}, {Jorge J.} and Pothana Saikumar and Singha, {Prajjal K.} and Dybdal-Hargreaves, {Nicholas F.} and Jeffery Chavez and Horning, {Aaron M.} and Jamie Parra and Kirma, {Nameer B}",
year = "2016",
doi = "10.1016/j.oraloncology.2016.05.007",
language = "English (US)",
volume = "59",
pages = "12--19",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma

AU - Gonzales, Cara B

AU - De La Chapa, Jorge J.

AU - Saikumar, Pothana

AU - Singha, Prajjal K.

AU - Dybdal-Hargreaves, Nicholas F.

AU - Chavez, Jeffery

AU - Horning, Aaron M.

AU - Parra, Jamie

AU - Kirma, Nameer B

PY - 2016

Y1 - 2016

N2 - Squamous cell carcinoma (SCC) comprises 90% of all head and neck cancers and has a poor survival rate due to late-stage disease that is refractive to traditional therapies. Epidermal growth factor receptor (EGFR) is over-expressed in greater than 80% of head and neck SCC (HNSCC). However, EGFR targeted therapies yielded little to no efficacy in clinical trials. This study investigated the efficacy of co-targeting EGFR and the anaplastic lymphoma kinase (ALK) whose promoter is hypomethylated in late-stage oral SCC (OSCC). We observed increased ALK activity in late-stage human OSCC tumors and invasive OSCC cell lines. We also found that while ALK inhibition alone had little effect on proliferation, co-targeting ALK and EGFR significantly reduced OSCC cell proliferation in vitro. Further analysis showed significant efficacy of combined treatment in HSC3-derived xenografts resulting in a 30% decrease in tumor volumes by 14 days (p < 0.001). Western blot analysis showed that co-targeting ALK and EGFR significantly reduced EGFR phosphorylation (Y1148) in HSC3 cells but not Cal27 cells. ALK and EGFR downstream signaling interactions are also demonstrated by Western blot analysis in which lone EGFR and ALK inhibitors attenuated AKT activity whereas co-targeting ALK and EGFR completely abolished AKT activation. No effects were observed on ERK1/2 activation. STAT3 activity was significantly induced by lone ALK inhibition in HSC3 cells and to a lower extent in Cal27 cells. Together, these data illustrate that ALK inhibitors enhance anti-tumor activity of EGFR inhibitors in susceptible tumors that display increased ALK expression, most likely through abolition of AKT activation.

AB - Squamous cell carcinoma (SCC) comprises 90% of all head and neck cancers and has a poor survival rate due to late-stage disease that is refractive to traditional therapies. Epidermal growth factor receptor (EGFR) is over-expressed in greater than 80% of head and neck SCC (HNSCC). However, EGFR targeted therapies yielded little to no efficacy in clinical trials. This study investigated the efficacy of co-targeting EGFR and the anaplastic lymphoma kinase (ALK) whose promoter is hypomethylated in late-stage oral SCC (OSCC). We observed increased ALK activity in late-stage human OSCC tumors and invasive OSCC cell lines. We also found that while ALK inhibition alone had little effect on proliferation, co-targeting ALK and EGFR significantly reduced OSCC cell proliferation in vitro. Further analysis showed significant efficacy of combined treatment in HSC3-derived xenografts resulting in a 30% decrease in tumor volumes by 14 days (p < 0.001). Western blot analysis showed that co-targeting ALK and EGFR significantly reduced EGFR phosphorylation (Y1148) in HSC3 cells but not Cal27 cells. ALK and EGFR downstream signaling interactions are also demonstrated by Western blot analysis in which lone EGFR and ALK inhibitors attenuated AKT activity whereas co-targeting ALK and EGFR completely abolished AKT activation. No effects were observed on ERK1/2 activation. STAT3 activity was significantly induced by lone ALK inhibition in HSC3 cells and to a lower extent in Cal27 cells. Together, these data illustrate that ALK inhibitors enhance anti-tumor activity of EGFR inhibitors in susceptible tumors that display increased ALK expression, most likely through abolition of AKT activation.

KW - Anaplastic lymphoma kinase

KW - Epidermal growth factor receptor

KW - Head and neck cancer

KW - Oral squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84980324638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980324638&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2016.05.007

DO - 10.1016/j.oraloncology.2016.05.007

M3 - Article

C2 - 27424178

AN - SCOPUS:84980324638

VL - 59

SP - 12

EP - 19

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -